Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2011 15:29

RNS Number : 5538M
GW Pharmaceuticals PLC
17 August 2011
 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

77,900 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

282,958 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

115,870 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

367,088 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

618,659 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

906,592 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

212,067 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

350,400 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

349,600 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 17 FEBRUARY 2011 TO: 17 AUGUST 2011

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

NIL ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

600,000 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

133,000,354 ORDINARY SHARES OF 0.1P EACH

 

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1980 557000

 

James Steel/Vijay Barathan, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRZDLFFFVFLBBD
Date   Source Headline
8th Sep 20152:37 pmRNSBlock Listing Application
17th Aug 20159:14 amRNSBlocklisting Interim Review
6th Aug 201512:28 pmRNSThird Quarter 2015 Financial Results
6th Aug 201511:45 amRNSFDA Fast Track and EMA Orphan Designations for CBD
23rd Jul 201512:00 pmRNSNotice of Results
16th Jul 20154:15 pmRNSAppointment of Director
16th Jul 201510:40 amRNSHolding(s) in Company
9th Jul 20154:57 pmRNSHolding(s) in Company
9th Jul 20154:24 pmRNSHolding(s) in Company
7th Jul 20153:23 pmRNSHolding(s) in Company
30th Jun 20157:00 amRNSDirector/PDMR Shareholding
24th Jun 20155:56 pmRNSDirector/PDMR Shareholding
12th Jun 20155:39 pmRNSDirector/PDMR Shareholding
11th Jun 201512:00 pmRNSSecond Ph3 Pivotal Study of Epidiolex in LGS
1st Jun 201510:19 amRNSBlock Listing Application
1st Jun 20157:54 amRNSHolding(s) in Company
1st Jun 20157:53 amRNSHolding(s) in Company
29th May 201511:13 amRNSHolding(s) in Company
19th May 201512:00 pmRNSAppoints US Executive; Relocates CEO to US
15th May 20155:43 pmRNSPurchase of Additional American Depositary Shares
11th May 20153:00 pmRNSPresenting at BAML 2015 Healthcare Conference
11th May 201512:00 pmRNSHalf Yearly Report
11th May 201512:00 pmRNSInitiates Ph3 Pivotal Study of Epidiolex in LGS
11th May 201511:45 amRNSHolding(s) in Company
11th May 201511:45 amRNSHolding(s) in Company
8th May 20154:22 pmRNSHolding(s) in Company
6th May 201512:00 pmRNSNotice of Results
6th May 201512:00 pmRNSInitiates Phase 2 Trial of CBDV in Epilepsy
6th May 20157:01 amRNSClosing of U.S. Public Offering of ADSs
1st May 20153:28 pmRNSHolding(s) in Company
1st May 20157:30 amRNSHolding(s) in Company
29th Apr 20157:00 amRNSPricing of U.S. Public Offering of ADSs
28th Apr 20157:00 amRNSProposed Public Offering of ADSs
27th Apr 201512:00 pmRNSUS Patent Allowance for Use of Cannabidivarin
24th Apr 201512:00 pmRNSOrphan Drug Designation for CBD in NHIE
23rd Apr 20157:00 amRNSNew Physician Reports of Epidiolex Treatment
21st Apr 201512:00 pmRNSStarts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome
14th Apr 20157:00 amRNSNew Epidiolex Data Released by AAN
1st Apr 20152:03 pmRNSHolding(s) in Company
31st Mar 201512:00 pmRNSStarts Ph 3 Trial for Epidiolex in Dravet Syndrome
17th Mar 20155:18 pmRNSHolding(s) in Company
17th Mar 20155:15 pmRNSHolding(s) in Company
25th Feb 201512:00 pmRNSPresenting at Upcoming Investor Conferences
17th Feb 20153:25 pmRNSBlocklisting Interim Review
16th Feb 20153:52 pmRNSHolding(s) in Company
16th Feb 20153:48 pmRNSHolding(s) in Company
9th Feb 20155:31 pmRNSDirector/PDMR Shareholding
5th Feb 20152:25 pmRNSResult of AGM
5th Feb 201512:00 pmRNSPresents at Leerink Global Healthcare Conference
4th Feb 201512:01 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.